Arovella Therapeutics Ltd has released a press release.
Positive pre-IND feedback from FDA for ALA-101
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Zolpimist Update
- Arovella completes manufacturing scale-up
- Arovella Completes $12.5M Placement - Funded to Phase 1 Data
- Pause in Trading
- Appendix 4D and Half Year Report
Later from Arovella Therapeutics
- Arovella receives R&D tax rebate of $3.0 million
- Arovella $20m Placement - fully funded to complete Phase 1
- Trading Halt
- Voluntary Suspension
- Arovella $15m Placement to fund Phase 1
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics